Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.
Onko sinulla jo Inderes-tili?
Follow this company like 1648 other investors.
Redeye returns with an updated take on the pick-and-shovel play Genovis following a site visit and change of lead analyst.
Redeye leaves a more elaborate take on Genovis following its Q3 2022 report. We are left with a positive bias after yesterday's report and make minor adjustments to our forecasts, resulting in an updated fair value range.
Redeye provides its initial take on Genovis’ Q3 2022 report, which came in just below our expectations on sales but significantly above our EBIT estimate.
Redeye returns with a follow-up note to Genovis’ Q2’22 report. We see a relatively weak report, although the growth in the Analytics segment (+31%) was a positive element.
Redeye provides its initial take on Genovis’ Q2’22 report, which came in below our expectations. We consider this a rather weak report from Genovis, although we note that the Analytics segment is continuing to grow solidly (+31%).
Genovis has signed a long-term licensing and supply agreement with a US based biotech company for the supply of SmartEnzymes[TM] to be used in the manufacturing of a clinical therapeutic agent. The new customer represents Genovis' second partner in the Bioprocess application area.
Redeye endorses Genovis entering into a service agreement with evitria AG for LC-MS analysis of recombinant antibodies.